免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / Time Limited Eating in Adolescents (Time LEAd): a Pilot Study (TimeLEAd)

Time Limited Eating in Adolescents (Time LEAd): a Pilot Study (TimeLEAd)

Study Description
Brief Summary:
The investigators propose a randomized controlled trial in 90 children (age 13-21y) with obesity recruited from clinical programs at the Children's Hospital Los Angeles (CHLA). Patients will be randomized to one of three treatment groups for a 12-week intervention: Group 1) Low sugar and carbohydrate diet (LSC, <90 gm carbohydrate (CHO)/day, <25 gm added sugar/day) + blinded CGM (used to monitor adherence and glycemic outcomes without real time feedback). Group 2) LSC+TLE (16-hour fast/8-hour feed for 3 days per week) + blinded CGM, Group 3) LSC+TLE+ real time feedback via CGM (to evaluate effect of providing CGM data on intervention efficacy).

Condition or disease Intervention/treatment Phase
Obesity, Childhood Behavioral: Low sugar and carbohydrate diet Behavioral: Time Limited Eating Device: Continuous Glucose Monitor Not Applicable

Show Show detailed description
Study Design
Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Time Limited Eating in Adolescents (Time LEAd): a Pilot Study
Actual Study Start Date : March 1, 2020
Estimated Primary Completion Date : January 30, 2022
Estimated Study Completion Date : August 30, 2023
Arms and Interventions
Arm Intervention/treatment
Experimental: LSC + blinded CGM
Group 1) Low sugar and carbohydrate diet (LSC, <90 gm carbohydrate (CHO)/day, <25 gm added sugar/day) + blinded CGM (used to monitor adherence and glycemic outcomes without real time feedback)
Behavioral: Low sugar and carbohydrate diet
Low sugar and carbohydrate diet (LSC, <90 gm carbohydrate (CHO)/day, <25 gm added sugar/day)
Other Name: LSC

Device: Continuous Glucose Monitor
CGM (used to monitor adherence and glycemic outcomes without real time feedback)
Other Name: CGM

Experimental: LSC+TLE + blinded CGM
Group 2) LSC+Time limited eating (TLE) (16-hour fast/8-hour feed for 3 days per week) + blinded CGM
Behavioral: Low sugar and carbohydrate diet
Low sugar and carbohydrate diet (LSC, <90 gm carbohydrate (CHO)/day, <25 gm added sugar/day)
Other Name: LSC

Behavioral: Time Limited Eating
16-hour fast/8-hour feed for 3 days per week
Other Name: TLE

Device: Continuous Glucose Monitor
CGM (used to monitor adherence and glycemic outcomes without real time feedback)
Other Name: CGM

Experimental: LSC+TLE+ real time feedback via CGM
Group 3) LSC+TLE+ real time feedback via CGM (to evaluate effect of providing CGM data on intervention efficacy).
Behavioral: Low sugar and carbohydrate diet
Low sugar and carbohydrate diet (LSC, <90 gm carbohydrate (CHO)/day, <25 gm added sugar/day)
Other Name: LSC

Behavioral: Time Limited Eating
16-hour fast/8-hour feed for 3 days per week
Other Name: TLE

Device: Continuous Glucose Monitor
CGM (used to monitor adherence and glycemic outcomes without real time feedback)
Other Name: CGM

Outcome Measures
Primary Outcome Measures :
  1. Change in Total Body Fat [ Time Frame: Baseline compared to week 13. ]
    Affect of dietary intervention on decrease in total body fat measured via DEXA scan.

  2. Change in BMI [ Time Frame: Baseline compared to week 13. ]
    Affect of dietary intervention on decrease in BMI z -score compared to baseline.


Secondary Outcome Measures :
  1. Beta cell dysfunction [ Time Frame: Baseline compared to week 13. ]
    Affect of dietary intervention on beta cell function as assessed fasting blood glucose level


Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   14 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. age 14-18
  2. BMI> 85th percentile
  3. parent, guardian or family member ages 18 years and older willing to participate

Exclusion Criteria:

  • Insulin requirement

    1. previous diagnosis of Prader Willi Syndrome, brain tumor or hypothalamic obesity
    2. serious mental conditions (e.g. developmental or intellectual disability or previously diagnosed eating disorder or positive screen at consent visit)
    3. physical, mental of other inability to participate in the assessments (e.g. inability to wear CGM, inability to be in the imaging modality without sedation, or inability to eat by mouth)
    4. previous or planned bariatric surgery
    5. current use of medication that impacts weight or executive functioning (e.g., antipsychotics, sedatives, hypnotics, off-label obesity medication)
    6. current psychotherapy regarding weight or eating behavior
    7. current participation in other interventional studies. In our experience, children younger than 13 years of age and older than 21 years would require different intervention/counseling strategies.
Contacts and Locations

Contacts
Layout table for location contacts
Contact: Alaina Vidmar, MD 323-361-3385 avidmar@chla.usc.edu
Contact: Michael Goran, pHD 323-361-8571 mgoran@chla.usc.edu

Locations
Layout table for location information
United States, California
Children's Hospital of Los Angeles Recruiting
Los Angeles, California, United States, 90027
Contact: Alaina P Vidmar, MD    323-361-3385    avidmar@chla.usc.edu   
Sponsors and Collaborators
Children's Hospital Los Angeles
Investigators
Layout table for investigator information
Principal Investigator: Alaina Vidmar, MD Children's Hospital Los Angeles
Tracking Information
First Submitted Date  ICMJE May 15, 2019
First Posted Date  ICMJE May 17, 2019
Last Update Posted Date February 17, 2021
Actual Study Start Date  ICMJE March 1, 2020
Estimated Primary Completion Date January 30, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 9, 2019)
  • Change in Total Body Fat [ Time Frame: Baseline compared to week 13. ]
    Affect of dietary intervention on decrease in total body fat measured via DEXA scan.
  • Change in BMI [ Time Frame: Baseline compared to week 13. ]
    Affect of dietary intervention on decrease in BMI z -score compared to baseline.
Original Primary Outcome Measures  ICMJE
 (submitted: May 15, 2019)
  • Reduction in Total Body Fat [ Time Frame: Baseline compared to week 13. ]
    Affect of dietary intervention on decrease in total body fat measured via DEXA scan.
  • BMI reduction [ Time Frame: Baseline compared to week 13. ]
    Affect of dietary intervention on decrease in BMI z -score compared to baseline.
  • Reduction in Liver Fat [ Time Frame: Baseline compared to week 13. ]
    Reduction in Liver Fat after dietary intervention as assessed by MRI.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: December 9, 2019)
Beta cell dysfunction [ Time Frame: Baseline compared to week 13. ]
Affect of dietary intervention on beta cell function as assessed fasting blood glucose level
Original Secondary Outcome Measures  ICMJE
 (submitted: May 15, 2019)
Beta cell dysfunction [ Time Frame: Baseline compared to week 13. ]
Affect of dietary intervention on beta cell function as assessed by the 90 minute c-peptide level after mixed meal tolerance test
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Time Limited Eating in Adolescents (Time LEAd): a Pilot Study
Official Title  ICMJE Time Limited Eating in Adolescents (Time LEAd): a Pilot Study
Brief Summary The investigators propose a randomized controlled trial in 90 children (age 13-21y) with obesity recruited from clinical programs at the Children's Hospital Los Angeles (CHLA). Patients will be randomized to one of three treatment groups for a 12-week intervention: Group 1) Low sugar and carbohydrate diet (LSC, <90 gm carbohydrate (CHO)/day, <25 gm added sugar/day) + blinded CGM (used to monitor adherence and glycemic outcomes without real time feedback). Group 2) LSC+TLE (16-hour fast/8-hour feed for 3 days per week) + blinded CGM, Group 3) LSC+TLE+ real time feedback via CGM (to evaluate effect of providing CGM data on intervention efficacy).
Detailed Description

The majority of adolescents with obesity demonstrate declining beta cell (β-cell) function and progressive insulin resistance over their lifetime.1 In our population of lower income minority teens, 1 in 3 have obesity or severe obesity and of those 30-50% go on to develop PD or T2D during adolescence or as young adults.1 Although diet and increased adiposity play a significant role in the pathogenesis of these conditions, the standard treatment model of intensive lifestyle modifications often result in modest decrease in BMI z-score of -0.1-0.2 SD.2, 3 There is a paucity of trials that have examined the effect of time limited eating (TLE) interventions in the treatment of youth with obesity.4 Novel dietary approaches like time limited eating have been shown to be effective for weight loss and improved glycemic control in adults with obesity but have not been examined in children.5, 6 A TLE approach involves interspersing normal daily caloric intake with 16-hour periods of calorie restriction/fasting several times a week.7-9 TLE may actually be more feasible, non-stigmatizing, flexible and effective for adolescents than alternatives like severe caloric restriction because it removes the need for intensive counting of daily caloric intake or macronutrient content and focuses on a straightforward task of consuming food during a pre-specified time period.4, 10, 11 One major limitation to implementing any dietary intervention in pediatric populations is concern for poor adherence and difficulty in reliably assessing compliance. We aim to overcome these issues with the use of continuous glucose monitoring (CGM) to monitor and promote adherence to the intervention and thus improve overall efficacy. In addition, the use of CGM will provide important outcome data related to overall glycemic response. Finally, we will evaluate whether providing individual feedback based on CGM data to subjects as real time biofeedback as part of the intervention, enhances efficacy. We propose a randomized controlled trial in 60 children (age 14-18) with obesity (BMI% > 95th percentile) recruited from clinical programs at the Children's Hospital Los Angeles (CHLA). Patients will be randomized to one of three treatment groups for a 12-week intervention: Group 1) Low sugar and carbohydrate diet (LSC, <90 gm carbohydrate (CHO)/day, <25 gm added sugar/day) + blinded CGM (used to monitor adherence and glycemic outcomes without real time feedback). Group 2) LSC+TLE (16-hour fast/8-hour feed for 5 days per week) + blinded CGM, Group 3) LSC+TLE+ real time feedback via CGM (to evaluate effect of providing CGM data on intervention efficacy).

We have 3 Specific Aims:

Aim 1. Test the efficacy of adding a TLE approach to a LSC intervention on body fat and weight loss (Group 2 vs. Group 1). Hypothesis 1: LSC+TLE will result in greater decrease in body fat and zBMI than LSC alone.

Aim 2. Test the efficacy of LSC+TLE compared to LSC alone on reduction on glycemic response (CGM) and psychosocial parameters (Group 2 vs. Group 1). Hypothesis 2: TLE+LSC will result in a greater improvement in glucose control (FBG) and psychosocial parameters.

Aim 3. Evaluate if CGM use is a feasible tool to determine dietary compliance to TLE type interventions and determine the impact of unblinded CGM on dietary intervention adherence and efficacy (Group 3 vs. Group 2). Hypothesis 3a: CGM will be a feasible tool to determine dietary compliance. Hypothesis 3b: Unblinded CGM data will result in 1) improved adherence to the dietary intervention as assessed by percent time in range when compared to those wearing a blinded CGM and 2) improve intervention effects.

Overall Impact: This research will generate new knowledge that can readily be integrated into clinical weight management programs to optimize their impact and accelerate healthy changes for youth with obesity. This dietary intervention could lead to global improvement and result in slowed disease progression, decreased complications and reduced prevalence of secondary comorbidities that arise from a lifetime of obesity.

Virtual Adaptation: To respond to the COVID-19 research restriction the study protocol was adapted for a 100% virtual model in which all study procedures, consent and outcome measures were collected virtually. For this cohort the aim was to recruit 10-12 completer per study arm with a maximum anticipated recruitment of 20-30 adolescents per group. For the virtual adaptation there is no DEXA scan or blood testing that is collected due to the in-person restriction.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Condition  ICMJE Obesity, Childhood
Intervention  ICMJE
  • Behavioral: Low sugar and carbohydrate diet
    Low sugar and carbohydrate diet (LSC, <90 gm carbohydrate (CHO)/day, <25 gm added sugar/day)
    Other Name: LSC
  • Behavioral: Time Limited Eating
    16-hour fast/8-hour feed for 3 days per week
    Other Name: TLE
  • Device: Continuous Glucose Monitor
    CGM (used to monitor adherence and glycemic outcomes without real time feedback)
    Other Name: CGM
Study Arms  ICMJE
  • Experimental: LSC + blinded CGM
    Group 1) Low sugar and carbohydrate diet (LSC, <90 gm carbohydrate (CHO)/day, <25 gm added sugar/day) + blinded CGM (used to monitor adherence and glycemic outcomes without real time feedback)
    Interventions:
    • Behavioral: Low sugar and carbohydrate diet
    • Device: Continuous Glucose Monitor
  • Experimental: LSC+TLE + blinded CGM
    Group 2) LSC+Time limited eating (TLE) (16-hour fast/8-hour feed for 3 days per week) + blinded CGM
    Interventions:
    • Behavioral: Low sugar and carbohydrate diet
    • Behavioral: Time Limited Eating
    • Device: Continuous Glucose Monitor
  • Experimental: LSC+TLE+ real time feedback via CGM
    Group 3) LSC+TLE+ real time feedback via CGM (to evaluate effect of providing CGM data on intervention efficacy).
    Interventions:
    • Behavioral: Low sugar and carbohydrate diet
    • Behavioral: Time Limited Eating
    • Device: Continuous Glucose Monitor
Publications * Vidmar AP, Goran MI, Naguib M, Fink C, Wee CP, Hegedus E, Lopez K, Gonzalez J, Raymond JK. Time limited eating in adolescents with obesity (time LEAd): Study protocol. Contemp Clin Trials. 2020 Aug;95:106082. doi: 10.1016/j.cct.2020.106082. Epub 2020 Jul 16.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 15, 2019)
90
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE August 30, 2023
Estimated Primary Completion Date January 30, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. age 14-18
  2. BMI> 85th percentile
  3. parent, guardian or family member ages 18 years and older willing to participate

Exclusion Criteria:

  • Insulin requirement

    1. previous diagnosis of Prader Willi Syndrome, brain tumor or hypothalamic obesity
    2. serious mental conditions (e.g. developmental or intellectual disability or previously diagnosed eating disorder or positive screen at consent visit)
    3. physical, mental of other inability to participate in the assessments (e.g. inability to wear CGM, inability to be in the imaging modality without sedation, or inability to eat by mouth)
    4. previous or planned bariatric surgery
    5. current use of medication that impacts weight or executive functioning (e.g., antipsychotics, sedatives, hypnotics, off-label obesity medication)
    6. current psychotherapy regarding weight or eating behavior
    7. current participation in other interventional studies. In our experience, children younger than 13 years of age and older than 21 years would require different intervention/counseling strategies.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 14 Years to 18 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Alaina Vidmar, MD 323-361-3385 avidmar@chla.usc.edu
Contact: Michael Goran, pHD 323-361-8571 mgoran@chla.usc.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03954223
Other Study ID Numbers  ICMJE CHLA-19-00193
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Alaina P. Vidmar, MD, Children's Hospital Los Angeles
Study Sponsor  ICMJE Children's Hospital Los Angeles
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Alaina Vidmar, MD Children's Hospital Los Angeles
PRS Account Children's Hospital Los Angeles
Verification Date February 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP